Literature DB >> 12414891

Elevated glucagon-like peptide-1-(7-36)-amide, but not glucose, associated with hyperinsulinemic compensation for fat feeding.

Gregg W van Citters1, Morvarid Kabir, Stella P Kim, Steven D Mittelman, Melvin K Dea, Patricia L Brubaker, Richard N Bergman.   

Abstract

We previously developed a canine model of central obesity and insulin resistance by supplementing the normal chow diet with 2 g cooked bacon grease/kg body weight. Dogs fed this fatty diet maintained glucose tolerance with compensatory hyperinsulinemia. The signal(s) responsible for this up-regulation of plasma insulin is unknown. We hypothesized that meal-derived factors such as glucose, fatty acids, or incretin hormones may signal beta-cell compensation in the fat-fed dog. We fed the same fat-supplemented diet for 12 wk to six dogs and compared metabolic responses with seven control dogs fed a normal diet. Fasting and stimulated fatty acid and glucose-dependent insulinotropic peptide concentrations were not increased by fat feeding, whereas glucose was paradoxically decreased, ruling out those three factors as signals for compensatory hyperinsulinemia. Fasting plasma glucagon-like peptide-1 (GLP-1) concentration was 2.5-fold higher in the fat-fed animals, compared with controls, and 3.4-fold higher after a mixed meal. Additionally, expression of the GLP-1 receptor in whole pancreas was increased 2.3-fold in the fat-fed dogs. The increase in both circulating GLP-1 and its target receptor may have increased beta-cell responsiveness to lower glucose. Glucose is not the primary cause of hyperinsulinemia in the fat-fed dog. Corequisite meal-related signals may be permissive for development of hyperinsulinemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12414891     DOI: 10.1210/jc.2002-020002

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Islet beta cell failure in type 2 diabetes.

Authors:  Marc Prentki; Christopher J Nolan
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

Review 2.  Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes.

Authors:  Zhuo Fu; Elizabeth R Gilbert; Dongmin Liu
Journal:  Curr Diabetes Rev       Date:  2013-01-01

3.  Impaired beta cell glucose sensitivity rather than inadequate compensation for insulin resistance is the dominant defect in glucose intolerance.

Authors:  A Mari; A Tura; A Natali; M Laville; M Laakso; R Gabriel; H Beck-Nielsen; E Ferrannini
Journal:  Diabetologia       Date:  2010-01-09       Impact factor: 10.122

4.  Beta cell compensation for insulin resistance in Zucker fatty rats: increased lipolysis and fatty acid signalling.

Authors:  C J Nolan; J L Leahy; V Delghingaro-Augusto; J Moibi; K Soni; M-L Peyot; M Fortier; C Guay; J Lamontagne; A Barbeau; E Przybytkowski; E Joly; P Masiello; S Wang; G A Mitchell; M Prentki
Journal:  Diabetologia       Date:  2006-07-26       Impact factor: 10.122

5.  Canine Geriatric Syndrome: A Framework for Advancing Research in Veterinary Geroscience.

Authors:  Brennen A McKenzie; Frances L Chen; Margaret E Gruen; Natasha J Olby
Journal:  Front Vet Sci       Date:  2022-04-21

6.  Pancreatic alpha-cells from female mice undergo morphofunctional changes during compensatory adaptations of the endocrine pancreas to diet-induced obesity.

Authors:  Beatriz Merino; Paloma Alonso-Magdalena; Mónica Lluesma; Patricia Ñeco; Alejandro Gonzalez; Laura Marroquí; Marta García-Arévalo; Angel Nadal; Ivan Quesada
Journal:  Sci Rep       Date:  2015-06-25       Impact factor: 4.379

7.  Physiological and pharmacological actions of glucagon like peptide-1 (GLP-1) in domestic animals.

Authors:  Jorge F A Model; Débora S Rocha; Alessa da C Fagundes; Anapaula S Vinagre
Journal:  Vet Anim Sci       Date:  2022-03-23

8.  Upregulated insulin secretion in insulin-resistant mice: evidence of increased islet GLP1 receptor levels and GPR119-activated GLP1 secretion.

Authors:  L Ahlkvist; K Brown; B Ahrén
Journal:  Endocr Connect       Date:  2013-03-18       Impact factor: 3.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.